Connecticut biologics regulations.

Who may administer PRP, exosomes and stem cells in Connecticut, and which agencies to check.

A physician at a desk reading regulatory documents

Who may administer biologics in Connecticut?

To administer biologic treatments in Connecticut, providers must meet specific licensing and credentialing requirements. Qualified professionals typically include licensed physicians (MD/DO) with additional certification in cell therapies. For more information, consult the Connecticut Department of Public Health's Practitioner Licensing page for relevant details on necessary credentials.

Official sources

Connecticut compliance guide.

FDA Compliance

Clinics offering biologics must comply with FDA regulations, particularly those outlined in FDA guidelines for HCT/P (Human Cells, Tissues, and Cellular and Tissue-Based Products). Providers should review the FDA's Code of Federal Regulations Title 21, Part 1271 to understand federal requirements for processing, storing, and using biologic products.

Connecticut State Regulations

Connecticut-specific regulations for biologic treatments are overseen by the state’s Department of Public Health. Clinics can access state-specific guidelines by visiting the Connecticut Department of Public Health website. Familiarizing yourself with these guidelines will support compliance and align clinic practices with state requirements.

Provider Qualifications

To administer biologic treatments in Connecticut, providers must meet specific licensing and credentialing requirements. Qualified professionals typically include licensed physicians (MD/DO) with additional certification in cell therapies. For more information, consult the Connecticut Department of Public Health's Practitioner Licensing page for relevant details on necessary credentials.

Patient Informed Consent

Securing informed consent is essential for biologic treatments. Connecticut clinics must provide patients with detailed information on the risks, potential benefits, alternative treatments, and the experimental status of certain biologics. Effective consent forms are transparent about the uncertainties surrounding stem cell therapies, helping patients make fully informed decisions.

Additional Compliance Requirements

Pre-Treatment and Post-Treatment Protocols

Standard Operating Procedures (SOPs) for pre- and post-treatment are recommended to ensure patient safety and adherence to best practices. These protocols should cover assessment, eligibility screening, and post-treatment follow-up for biologic therapies.

Medical Liability Insurance

Clinics offering biologics should maintain adequate medical liability insurance to cover potential risks associated with stem cell and other biologic treatments. Connecticut insurance providers often offer tailored policies for regenerative medicine practitioners.

Marketing Compliance

Marketing of biologic therapies must avoid false or misleading claims about treatment outcomes. Connecticut clinics should follow FDA guidelines on marketing, avoiding terms that imply guaranteed results. Detailed marketing rules can be found on the FDA’s Health Fraud Scams page.

This guide is a general summary to help clinics understand compliance requirements for biologics in Connecticut. It is not legal advice. Regulations change; consult legal counsel and the agencies above before acting on it.

Connecticut: common questions.

Who can administer stem cells, PRP and exosomes in Connecticut?
To administer biologic treatments in Connecticut, providers must meet specific licensing and credentialing requirements. Qualified professionals typically include licensed physicians (MD/DO) with additional certification in cell therapies. For more information, consult the Connecticut Department of Public Health's Practitioner Licensing page for relevant details on necessary credentials. This is a general summary, not legal advice. Confirm with the state board.
Are stem cell and exosome therapies FDA-approved in Connecticut?
FDA rules are federal, so they apply in Connecticut as everywhere else. Exosome and stem cell therapies are not FDA-approved for therapeutic use, and PRP applications are considered off-label.
Do I need an IRB-approved study to offer biologics in Connecticut?
Investigational treatment belongs inside a reviewed study with proper informed consent. IRB review is not FDA authorisation: culture-expanded and other more-than-minimally-manipulated cell products generally need an IND before use in people.
How do I start offering biologics in Connecticut?
Start with the live webinar, then a discovery call and live training. After that we verify your Connecticut licence, protocol, product sourcing, consent process and advertising before you are listed for patient inquiries.

Practising in Connecticut? Start with the webinar.

Live on Zoom, Tuesdays at 12:00 PM ET. See how the model works before you commit to anything.